All Access

Biotech Deals

Biotech Deals Alert

Alert

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

pittsburgh

atlanta

san-diego

charlotte

boulder

washington-dc

kansas-city

dallas

denver

detroit

des-moines

austin

boston

chicago

cleveland

columbus

houston

indianapolis

miami

nashville

new-orleans

nw-arkansas

philadelphia

phoenix

portland

richmond

salt-lake-city

san-antonio

san-francisco

seattle

tampa-bay

twin-cities

raleigh

huntsville

colorado-springs

axios-local

axios-pro

axios-live

the-axios-show

CapVest Partners acquired a majority stake in German drugmaker Stada Arzneimittel AG, reportedly valuing the company at about €10 billion.

Why it matters: Stada had reportedly been exploring an IPO.

Zoom in: Announced Monday, the transaction is set to close early next year. 

London-based CapVest will invest alongside current stakeholders Bain and Cinven, who will retain a minority stake. 

Catch up quick: Bain and Cinven took Stada private for €5.3 billion in 2017. 

In August 2023, the owners began weighing Stada's sale and IPO options, Bloomberg reported at the time.

In March of this year, an IPO was postponed to September following market volatility, per Bloomberg.

How it works: Stada makes consumer health care products, generic drugs, and rare and chronic disease medications.

The big picture: Other recent pharma PE buyouts this year include Bain Capital co-leading an investment in PCI Pharma Services, valuing it at $10 billion.

CapVest takeover reportedly values Stada at €10B

The deal follows reports of Stada's plans to IPO.

Illustration of a pattern of caduceus gradually becoming dollar signs

CapVest Partners acquired a majority stake in German drugmaker Stada Arzneimittel AG, <a class="gtmContentClick" data-vars-link-text="reportedly valuing" data-vars-click-url="https://www.wsj.com/finance/investing/capvest-to-acquire-majority-stake-in-germanys-stada-f66e94ae?gaa_at=eafs&amp;gaa_n=ASWzDAhhNZQaNRv13aT65oy4hMYCuqmqu7c2ilgT6zmbqshYdDt0swtmx-wlCiuBD5Y%3D&amp;gaa_ts=68b6f24d&amp;gaa_sig=iYs7jMDpslfJpA37xOdcbMMV6i0cfQnfB7MTd7-gW5qBGuWZokEP5TjZ3UHpcahgV8i7yeu7uEsU8rN-nhaNQg%3D%3D" data-vars-content-id="efb7be79-b2e9-497d-9a2a-9e24fb050796" data-vars-headline="CapVest takeover reportedly values Stada at €10B" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.wsj.com/finance/investing/capvest-to-acquire-majority-stake-in-germanys-stada-f66e94ae?gaa_at=eafs&amp;gaa_n=ASWzDAhhNZQaNRv13aT65oy4hMYCuqmqu7c2ilgT6zmbqshYdDt0swtmx-wlCiuBD5Y%3D&amp;gaa_ts=68b6f24d&amp;gaa_sig=iYs7jMDpslfJpA37xOdcbMMV6i0cfQnfB7MTd7-gW5qBGuWZokEP5TjZ3UHpcahgV8i7yeu7uEsU8rN-nhaNQg%3D%3D" target="_blank">reportedly valuing</a> the company at about €10 billion.Why it matters: Stada had reportedly been exploring an IPO.

CapVest takeover reportedly values Stada at €10B

What to read next